Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 161975-39-9 | MDL No. : | MFCD02082459 |
Formula : | C12H23NO5S | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | RXNQBVRCZIYUJK-UHFFFAOYSA-N |
M.W : | 293.38 | Pubchem ID : | 2765838 |
Synonyms : |
|
Num. heavy atoms : | 19 |
Num. arom. heavy atoms : | 0 |
Fraction Csp3 : | 0.92 |
Num. rotatable bonds : | 6 |
Num. H-bond acceptors : | 5.0 |
Num. H-bond donors : | 0.0 |
Molar Refractivity : | 76.26 |
TPSA : | 81.29 Ų |
GI absorption : | High |
BBB permeant : | No |
P-gp substrate : | No |
CYP1A2 inhibitor : | Yes |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -7.18 cm/s |
Log Po/w (iLOGP) : | 2.96 |
Log Po/w (XLOGP3) : | 1.28 |
Log Po/w (WLOGP) : | 2.31 |
Log Po/w (MLOGP) : | 1.21 |
Log Po/w (SILICOS-IT) : | 0.38 |
Consensus Log Po/w : | 1.63 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -2.07 |
Solubility : | 2.5 mg/ml ; 0.00852 mol/l |
Class : | Soluble |
Log S (Ali) : | -2.59 |
Solubility : | 0.76 mg/ml ; 0.00259 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -1.72 |
Solubility : | 5.54 mg/ml ; 0.0189 mol/l |
Class : | Soluble |
PAINS : | 0.0 alert |
Brenk : | 1.0 alert |
Leadlikeness : | 0.0 |
Synthetic accessibility : | 2.88 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P280-P301+P312-P302+P352-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
2.19 g | With sodium iodide In acetoneReflux | To tert-butyl 4-(((methylsulfonyl)oxy)methyl)piperidine-1-carboxylate (2.57 g, 8.8 mmol) in acetone (60 mL) was added sodium iodide (2.63 g, 17.5 mmol). The yellow solution formed was heated at reflux overnight. The resulting orange suspension formed was cooled to room temperature and filtered. The filtrate was concentrated in vacuo and the residue partitionedbetween DCM (100 ml) and water (20 ml). The organic portion was dried (MgSO4) and treated with silica (10 g). This was filtered and the filtrate concentrated to give the title compound as an orange oil (2.19 g);1H NMR (400MHz, ODd3) o 1.14 (2H, dq), 1.48 (9H, 5), 1.57-1.70 (1H, m), 1.82-1.90 (2H, m), 2.73 (2H, t), 3.12 (2H, d), 4.10-4.20 (2H, m). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
85.4% | With lithium bromide In acetoneReflux | Amixture of 2 (1eq, 11.72 g, 40 mmol) and lithium bromide (5eq,17.20 g, 200 mmol) in acetone (80 mL) was heated to reflux overnight.The mixture was evaporated, then the residue was partitionedbetween EtOAc and water. The organic layer was washedwith s brine, dried over Na2SO4, filtered, and evaporated to offer the title product 3 as pale yellow oil (9.46 g, 85.40percent yield). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
6.87 g | at 80℃; for 24 h; | 4-(cyanomethyl)piperidine-1-carboxylate tert-Butyl 4-[(methylsulfonyl)oxy]methyl}piperidine-1-carboxylate (15.3 g) was dissolved in ethanol (80 mL), water (20 mL) and sodium cyanide (4.0 g, 80 mmol) were added, and stirring was conducted at 80° C. for 24 hours. Ethanol was distilled off, water and ethyl acetate were added, and then the resultant mixture was subject to Celite filtration, followed by extraction with ethyl acetate. The organic layer was washed with saturated brine, dried over anhydrous sodium sulfate and concentrated under a reduced pressure, and the obtained residue was purified by using silica gel column chromatography (hexane:ethyl acetate=3:1→2:1) to give tert-butyl 4-(cyanomethyl)piperidine-1-carboxylate (6.87 g, 77percent, 3 steps) as a white solid. 1H-NMR (CDCl3) δ: 1.21-1.31 (2H, m), 1.46 (9H, s), 1.78-1.86 (3H, m), 2.31 (2H, d, J=6.4 Hz), 2.64-2.78 (2H, m), 4.07-4.21 (2H, m). |
[ 141699-59-4 ]
tert-Butyl 4-((methylsulfonyl)oxy)piperidine-1-carboxylate
Similarity: 0.91
[ 129888-60-4 ]
tert-Butyl 3-((methylsulfonyl)oxy)piperidine-1-carboxylate
Similarity: 0.89
[ 404577-34-0 ]
(R)-1-N-Boc-3-Methanesulfonyloxypiperidine
Similarity: 0.89
[ 940890-90-4 ]
(S)-tert-Butyl 3-((methylsulfonyl)oxy)piperidine-1-carboxylate
Similarity: 0.89
[ 141699-57-2 ]
tert-Butyl 3-((methylsulfonyl)oxy)pyrrolidine-1-carboxylate
Similarity: 0.82
[ 141699-59-4 ]
tert-Butyl 4-((methylsulfonyl)oxy)piperidine-1-carboxylate
Similarity: 0.91
[ 129888-60-4 ]
tert-Butyl 3-((methylsulfonyl)oxy)piperidine-1-carboxylate
Similarity: 0.89
[ 404577-34-0 ]
(R)-1-N-Boc-3-Methanesulfonyloxypiperidine
Similarity: 0.89
[ 940890-90-4 ]
(S)-tert-Butyl 3-((methylsulfonyl)oxy)piperidine-1-carboxylate
Similarity: 0.89
[ 141699-57-2 ]
tert-Butyl 3-((methylsulfonyl)oxy)pyrrolidine-1-carboxylate
Similarity: 0.82
[ 141699-59-4 ]
tert-Butyl 4-((methylsulfonyl)oxy)piperidine-1-carboxylate
Similarity: 0.91
[ 129888-60-4 ]
tert-Butyl 3-((methylsulfonyl)oxy)piperidine-1-carboxylate
Similarity: 0.89
[ 404577-34-0 ]
(R)-1-N-Boc-3-Methanesulfonyloxypiperidine
Similarity: 0.89
[ 940890-90-4 ]
(S)-tert-Butyl 3-((methylsulfonyl)oxy)piperidine-1-carboxylate
Similarity: 0.89
[ 123855-51-6 ]
tert-Butyl 4-(hydroxymethyl)piperidine-1-carboxylate
Similarity: 0.71